Printer Friendly
The Free Library
21,435,892 articles and books
Member login
User name  
Password 
 
Join us Forgot password?

ISTA Pharmaceuticals, Irvine, CA, Nov. 2 (DDMAC).

The agency reviewed a journal advertisement for Vitrase (hyaluronidase Hyaluronidase

Any one of a family of enzymes, also known as hyaluronate lyases or spreading factors, produced by mammals, reptiles, insects, and bacteria, which catalyze the breakdown of hyaluronic acid.
 injection; Ovine ovine

pertaining to, characteristic of, or derived from sheep.


ovine atopic dermatitis
symmetrical erythema, alopecia, lichenification, excoriation on woolless areas; sporadic cases, recur each summer.
, 200 USP Units/mL and Lyophilized, Ovine, 6200 USP Units) and concluded that the ad was false and misleading because it failed to reveal material facts and minimized the associated risks.

According to the approved product labeling, Vitrase is indicated as an adjuvant to increase the absorption and dispersion of other injected drugs, hypo dermoclysis, and as an adjunct in subcutaneous urography urography /urog·ra·phy/ (u-rog´rah-fe) radiography of any part of the urinary tract.

ascending urography , cystoscopic urography retrograde u.
 for improving resorption or radiopaque agents.

DDMAC stated the ad failed to include any of the warnings associated with the use of the drug or the precautions regarding the incompatibility with furosemide furosemide /fu·ro·sem·ide/ (fu-ro´se-mid) a loop diuretic used in the treatment of edema and hypertension.

fu·ro·se·mide
n.
A white to yellow crystalline powder used as a diuretic.
, benzodiazepines and phenytoin phenytoin /phen·y·to·in/ (fen´i-toin?) an anticonvulsant used in the control of various kinds of epilepsy and of seizures associated with neurosurgery.

phen·y·to·in
n.
. By omitting these risks, the journal ad misleadingly suggested that Vitrase is safer than has been demonstrated, the agency concluded. F-B: Doc. 13672W

ISTA Pharmaceuticals's advertisement:

Failed to include any of the warnings associated with the use of the drug [Vitrase].

Neglected to reveal material facts and minimized the associated risks.

Failed to include contraindications with furosemide, benzodiazepines and phenytoin.
COPYRIGHT 2005 Washington Information Source, Inc.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2005 Gale, Cengage Learning. All rights reserved.

 Reader Opinion

Title:

Comment:



 

Article Details
Printer friendly Cite/link Email Feedback
Title Annotation:DDMAC PROMO UNTITLED LETTERS
Publication:Warning Letter Bulletin
Date:Dec 1, 2005
Words:168
Previous Article:Critical Therapeutics, Lexington, MA, Nov. 8 (DDMAC).
Next Article:Nidpoe letter.
Topics:



Related Articles
DDMAC UNTITLED LETTERS: 7085W.
DDMAC promo untitled letter.
AstraZeneca Pharmaceuticals LP, Wilmington, DE, March 8 (DDMAC).
Boehringer Ingelheim Pharmaceuticals, Ridgefield, CT, March 22 (DDMAC).
Pfizer, New York, April 13 (DDMAC).
Bayer Pharmaceuticals, West Haven, CT, April 13 (DDMAC).
Watson Pharmaceuticals, Morristown, NJ, May 2 (DDMAC).
Endo Pharmaceuticals, Chadds Ford, PA, June 28 (DDMAC).
Actelion Pharmaceuticals US, San Francisco, July 20 (DDMAC).
Advertising risk guidance seen by January.

Terms of use | Copyright © 2013 Farlex, Inc. | Feedback | For webmasters | Submit articles